Molecular and clinical aspects of targeting the VEGF pathway in tumors.
about
Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumorsBevacizumab in the treatment of metastatic breast cancer: friend or foe?Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Tumor control versus adverse events with targeted anticancer therapies.Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population.In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.
P2860
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@en
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@nl
type
label
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@en
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@nl
prefLabel
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@en
Molecular and clinical aspects of targeting the VEGF pathway in tumors.
@nl
P2093
P2860
P356
P1433
P1476
Molecular and clinical aspects of targeting the VEGF pathway in tumors
@en
P2093
Desmond N Carney
Grzegorz Korpanty
Laura A Sullivan
Rolf A Brekken
P2860
P304
P356
10.1155/2010/652320
P577
2010-06-10T00:00:00Z